A Phase II, Multi-center, Randomized, Double-Blind, Placebo Controlled, Dose Response Study to Evaluate the Safety and Efficacy of Two Different Doses of Abatacept (BMS-188667) Administered Intravenously to Japanese Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate
A Phase II, Multi-center, Randomized, Double-Blind, Placebo Controlled, Dose Response Study to Evaluate the Safety and Efficacy of Two Different Doses of Abatacept (BMS-188667) Administered Intravenously to Japanese Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate
The purpose of this study is to demonstrate that Abatacept combined with Methotrexate will demonstrate a dose response efficacy in Japanese subjects with active Rheumatoid Arthritis similar to the dose response efficacy previously observed in the International clinical trials.
Inclusion Criteria:
Exclusion Criteria:
Goshogawara-Shi, Aomori 037-0053, Japan
Kitakyushu-Shi, Fukuoka 807-8555, Japan
Higashi-Hiroshima-Shi, Hiroshima 739-0002, Japan
Kanzaki-Gun, Hyōgo 679-2414, Japan
Kato-Gun, Hyōgo 673-1462, Japan
Hitachi-Shi, Ibaraki 316-0035, Japan
Sagamihara-Shi, Kanagawa 228-8522, Japan
Tsukubo-Gun, Okayama-ken 701-0304, Japan
Kawachinagano-Shi, Osaka 86-0008, Japan
Ureshino-Shi, Saga-ken 843-0301, Japan
Iruma-Gun, Saitama 350-0495, Japan
Kawagoe-Shi, Saitama 350-8550, Japan
Kitamoto-Shi, Saitama 364-0026, Japan
Kawachigun, Tochigi 329-1104, Japan
Arakawa-Ku, Tokyo 116-0011, Japan
Bunkyo-Ku, Tokyo 113-0022, Japan
Bunkyo-Ku, Tokyo 113-8519, Japan
Setagaya-Ku, Tokyo 155-0032, Japan
Shinjuku-Ku, Tokyo 162-0054, Japan
Takaoka-Shi, Toyama 933-8525, Japan